Immatics NV
NASDAQ:IMTX

Watchlist Manager
Immatics NV Logo
Immatics NV
NASDAQ:IMTX
Watchlist
Price: 4.74 USD 1.07% Market Closed
Market Cap: 576.1m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one IMTX stock under the Base Case scenario is 6.27 USD. Compared to the current market price of 4.74 USD, Immatics NV is Undervalued by 24%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IMTX Relative Value
Base Case
6.27 USD
Undervaluation 24%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.3
P/S
P/S
Price to Sales
3.3
vs History
96
vs Industry
62
Median 3Y
6.4
Median 5Y
10.9
Industry
6.8
Forward
8.7
More Details
33.8
P/E
P/E
Price to Earnings
33.8
vs History
6
vs Industry
9
Median 3Y
-7.4
Median 5Y
-4.9
Industry
21.9
Forward
-3.2
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
1
Median 3Y
-3.2
Median 5Y
-5.5
Industry
19.5
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
8
Median 3Y
-5.8
Median 5Y
-5.8
Industry
23.4
More Details
0.9
P/B
P/B
Price to Book Value
0.9
vs History
92
vs Industry
50
Median 3Y
2.9
Median 5Y
3.8
Industry
2.4
More Details
Negative
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
77
Median 3Y
2.9
Median 5Y
7
Industry
7.2
Forward
-1.3
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.1
More Details
2.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
2.9
vs History
20
vs Industry
10
Median 3Y
-4.1
Median 5Y
-5.1
Industry
3.9
Forward
0.9
More Details
2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
2
vs History
20
vs Industry
9
Median 3Y
-3.7
Median 5Y
-4.8
Industry
3.8
Forward
0.5
More Details
0.5
EV/OCF
EV/OCF
Enterprise Value to OCF
0.5
vs History
39
vs Industry
2
Median 3Y
0.5
Median 5Y
-3.4
Industry
4.4
More Details
0.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
0.4
vs History
30
vs Industry
9
Median 3Y
-3
Median 5Y
-3.8
Industry
3.5
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
55
Median 3Y
7.9
Median 5Y
11.6
Industry
4.4
More Details

Multiples Across Competitors

IMTX Competitors Multiples
Immatics NV Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
DE
Immatics NV
NASDAQ:IMTX
576.1m USD 3.3 33.8 2.9 2
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 448 623 -168 482 -204 590.9 -202 256.3
US
Abbvie Inc
NYSE:ABBV
325B USD 5.7 78.2 15 22.1
US
Amgen Inc
NASDAQ:AMGN
146.5B USD 4.3 24.7 13.5 22.3
US
Gilead Sciences Inc
NASDAQ:GILD
127.6B USD 4.4 21.4 9.4 12.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.7B USD 10.2 -114 24.2 25.3
US
Epizyme Inc
F:EPE
94.1B EUR 1 987.4 -507.1 -552.2 -537.5
AU
CSL Ltd
ASX:CSL
117.1B AUD 4.9 27.3 16.9 21.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
64.3B USD 4.6 14.3 12.9 14.4
US
Seagen Inc
F:SGT
39.3B EUR 19.1 -58.7 -63.2 -57
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
37.2B USD 15.8 -137.9 -615.3 -308.3
P/S Multiple
Revenue Growth P/S to Growth
DE
Immatics NV
NASDAQ:IMTX
Average P/S: 3 222 789.3
3.3
-21%
N/A
FR
Pharnext SCA
OTC:PNEXF
35 448 623
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.3
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.4
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.2
10%
1
US
E
Epizyme Inc
F:EPE
1 987.4
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.6
5%
0.9
US
S
Seagen Inc
F:SGT
19.1
30%
0.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
15.8
29%
0.5
P/E Multiple
Earnings Growth PEG
DE
Immatics NV
NASDAQ:IMTX
Average P/E: 33.3
33.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -168 482 N/A N/A
US
Abbvie Inc
NYSE:ABBV
78.2
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.7
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
21.4
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -114 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -507.1 N/A N/A
AU
CSL Ltd
ASX:CSL
27.3
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.3
7%
2
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -137.9 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DE
Immatics NV
NASDAQ:IMTX
Average EV/EBITDA: 13.5
2.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -204 590.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.5
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.4
7%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
18%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -552.2 N/A N/A
AU
CSL Ltd
ASX:CSL
16.9
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.9
14%
0.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -615.3 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DE
Immatics NV
NASDAQ:IMTX
Average EV/EBIT: 17.2
2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -202 256.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.1
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.3
31%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.3
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -537.5 N/A N/A
AU
CSL Ltd
ASX:CSL
21.1
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.4
13%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -57 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -308.3 N/A N/A

See Also

Summary
IMTX intrinsic value, competitors valuation, and company profile.
DCF Valuation
IMTX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
IMTX stock valuation using valuation multiples.
Wall Street Estimates
IMTX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
IMTX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 255,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.